Insights

Connecting the Dots: Anticipation Requires More Than Listing Scattered Claim Elements, <i>PTAB Litigation Blog</i>

Connecting the Dots: Anticipation Requires More Than Listing Scattered Claim Elements, PTAB Litigation Blog

Visit the Jones Day PTAB Litigation Blog.

On November 30, 2016, the PTAB issued decisions on the institution of inter partes reviews of U.S. Patent No. 6,667,061 (the ’061 patent), which relates to formulations for injectable suspensions having increased viscosity.  The ’061 patent is owned by Alkermes Pharma Ireland, Ltd. and Alkermes Controlled Therapeutics, Inc. (“Alkermes”), and is listed in the Orange Book in connection with formulations of risperidone (Janssen Pharmaceuticals, Inc.), naltrexone (Alkermes, Inc.), and synthetic exenatide (AstraZeneca AB).  Luye Pharma Group Ltd. (“Luye”) filed a pair of petitions challenging all but three of the twenty-three claims in the ’061 patent.  In the case of IPR2016-01095, the PTAB declined to institute an IPR.

Read the full article at ptablitigationblog.com.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.